Letter: interpretation of the BESST trial in the context of baseline antidepressant and neuromodulator use-Authors' reply
- PMID: 38153284
- DOI: 10.1111/apt.17838
Letter: interpretation of the BESST trial in the context of baseline antidepressant and neuromodulator use-Authors' reply
Comment on
-
Letter: interpretation of the BESST trial in the context of baseline antidepressant and neuromodulator use.Aliment Pharmacol Ther. 2024 Jan;59(2):291-292. doi: 10.1111/apt.17800. Aliment Pharmacol Ther. 2024. PMID: 38153276 Free PMC article. No abstract available.
References
REFERENCES
-
- Hiramoto B, Chan WW. Letter: interpretation of the BESST trial in the context of baseline antidepressant and neuromodulator use. Aliment Pharmacol Ther. 2024;59:291-292.
-
- Parkman HP, Yates KP, Sarosiek I, Bulat RS, Abell TL, Koch KL, et al. Buspirone for early satiety and symptoms of gastroparesis: a multi-centre, randomised, placebo-controlled, double-masked trial (BESST). Aliment Pharmacol Ther. 2023;57:1272-1289.
-
- Tack J, Janssen P, Masaoka T, Farré R, Van Oudenhove L. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin Gastroenterol Hepatol. 2012;10:1239-1245.
-
- Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology. 1998;115:1346-1352.
-
- Pasricha PJ, Grover M, Yates KP, Abell TL, Koch KL, McCallum RW, et al. Progress in gastroparesis - a narrative review of the work of the Gastroparesis Clinical Research Consortium. Clin Gastroenterol Hepatol. 2022;20:2684-2695.e3.
Publication types
LinkOut - more resources
Full Text Sources